Guidant Corp. will likely deem a sweetened $25 billion bid from Boston Scientific superior to its existing $23 billion takeover offer from Johnson & Johnson, setting in motion the next phase of the bidding war for the medical-device maker, analysts said on Friday.
*For more on this story,
read the full Reuters article.
